A PK–PD Model for Predicting the Impact of Age, CYP2C9, and VKORC1 Genotype on Individualization of Warfarin Therapy
- 14 February 2007
- journal article
- Published by Wiley in Cancer Cell
- Vol. 81 (4), 529-538
- https://doi.org/10.1038/sj.clpt.6100084
Abstract
The aim of this study was to characterize the relationship between warfarin concentrations and international normalized ratio (INR) response and to identify predictors important for dose individualization. S‐ and R‐warfarin concentrations, INR, and CYP2C9 and VKORC1 genotypes from 150 patients were used to develop a population pharmacokinetic/pharmacodynamic model in NONMEM. The anticoagulant response was best described by an inhibitory EMAX model, with S‐warfarin concentration as the only exposure predictor for response. Delay between exposure and response was accounted for by a transit compartment model with two parallel transit compartment chains. CYP2C9 genotype and age were identified as predictors for S‐warfarin clearance, and VKORC1 genotype as a predictor for warfarin sensitivity. Predicted INR curves indicate important steady‐state differences between patients with different sets of covariates; differences that cannot be foreseen from early INR assessments alone. It is important to account for CYP2C9 and VKORC1 genotypes and age to improve a priori and a posteriori individualization of warfarin therapy. Clinical Pharmacology & Therapeutics (2007) 81, 529–538. doi:10.1038/sj.clpt.6100084; published online 14 February 2007Keywords
This publication has 22 references indexed in Scilit:
- The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimenBlood, 2005
- Common VKORC1 and GGCX polymorphisms associated with warfarin doseThe Pharmacogenomics Journal, 2005
- CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differencesClinical Pharmacology & Therapeutics, 2004
- Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2Nature, 2004
- Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarinThe Pharmacogenomics Journal, 2003
- Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearanceClinical Pharmacology & Therapeutics, 2002
- Pharmacogenetics of Warfarin Elimination and its Clinical ImplicationsClinical Pharmacokinetics, 2001
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999
- Oral AnticoagulantsChest, 1995
- Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in manClinical Pharmacology & Therapeutics, 1974